BD rides high on product demand across segments, but fourth-quarter fiscal 2025 results may face pressure from global market ...

Waters Corp reports record Q3 2025 sales and profit growth, raises full-year guidance, and highlights new product launches and BD deal synergies.

Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and delays clinical relapse in patients with high-risk chronic lymphocytic leukemia (CLL), ...

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...

Discover how dormant microbes in soil impact plant root colonization, revealing their vital role in agriculture.

New research has updated the understanding of how sugars, known as glycans, help immune cells move into the skin in the ...

For years, doctors have relied on familiar vital signs—heart rate, blood pressure, temperature and oxygen levels—to monitor someone's health. But researchers at the University of Missouri believe one ...

Gross margins in the third quarter of 2025 were approximately 48.5%, versus 54.9% in the third quarter of 2024; and non-GAAP ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.